COMT val158met moderation of dopaminergic drug effects on cognitive function: A critical review

Pharmacogenomics Journal

Volumn 16, Issue 5, 2016, Pages 430-438

  Schacht, J P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CATECHOL METHYLTRANSFERASE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; METHYLPHENIDATE; NEUROLEPTIC AGENT; TOLCAPONE; CATECHOL METHYLTRANSFERASE INHIBITOR; COMT PROTEIN, HUMAN; DRD1 PROTEIN, HUMAN; DRD2 PROTEIN, HUMAN;

ALLELE; COGNITION; COMT GENE; CONTROLLED CLINICAL TRIAL (TOPIC); DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXECUTIVE FUNCTION; GENETIC VARIATION; GENOTYPE; HUMAN; PHARMACOGENETICS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SELECTIVE ATTENTION; SINGLE NUCLEOTIDE POLYMORPHISM; WORKING MEMORY; AGONISTS; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENE FREQUENCY; GENETICS; HETEROZYGOTE; HOMOZYGOTE; METABOLISM; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETIC VARIANT; PHENOTYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; COGNITION; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 84973164066     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.43     Document Type: Review

References (84)

1. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217
2. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000; 408: 199-203
3. De Mei C, Ramos M, Iitaka C, Borrelli E. Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 2009; 9: 53-58
4. Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 1991; 40: 657-671
5. Durstewitz D, Seamans JK. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol Psychiatry 2008; 64: 739-749
6. Cropley VL, Fujita M, Innis RB, Nathan PJ. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 2006; 59: 898-907
7. Haber SN. The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014; 282C: 248-257
8. Dreyer JK, Herrik KF, Berg RW, Hounsgaard JD. Influence of phasic and tonic dopamine release on receptor activation. J Neurosci 2010; 30: 14273-14283
9. Cools R, D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry 2011; 69: e113-e125
10. Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 1997; 11: 151-162
11. Goldman-Rakic PS, Muly EC 3rd, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000; 31: 295-301
12. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 1997; 17: 8528-8535
13. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 1998; 18: 2697-2708
14. Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, Herman MM, et al. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 2003; 116: 127-137
15. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250
16. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807-821
17. Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry 2008; 13: 821-827
18. Craddock N, Owen MJ, O'Donovan MC. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol Psychiatry 2006; 11: 446-458
19. Lachman HM. Does COMT val158met affect behavioral phenotypes: yes, no, maybe? Neuropsychopharmacology 2008; 33: 3027-3029
20. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24
21. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23: 33-41
22. Cheuk DK, Wong V. Meta-Analysis of association between a catechol-Omethyltransferase gene polymorphism and attention deficit hyperactivity disorder. Behav Genet 2006; 36: 651-659
23. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-Analysis of case-control studies. Mol Psychiatry 2005; 10: 765-770
24. Rosa A, Peralta V, Cuesta MJ, Zarzuela A, Serrano F, Martinez-Larrea A, et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 2004; 161: 1110-1112
25. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002; 159: 652-654
26. Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, et al. Executive subprocesses in working memory: relationship to catechol-Omethyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60: 889-896
27. Barnett JH, Scoriels L, Munafo MR. Meta-Analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008; 64: 137-144
28. Witte AV, Floel A. Effects of COMT polymorphisms on brain function and behavior in health and disease. Brain Res Bull 2012; 88: 418-428
29. Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 2009; 32: 267-287
30. Gelernter J. Genetics of complex traits in psychiatry. Biol Psychiatry 2015; 77: 36-42
31. Muller U, von Cramon DY, Pollmann S. D1- versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 1998; 18: 2720-2728
32. Narayanan NS, Land BB, Solder JE, Deisseroth K, DiLeone RJ. Prefrontal D1 dopamine signaling is required for temporal control. Proc Natl Acad Sci USA 2012; 109: 20726-20731
33. Chudasama Y, Robbins TW. Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology 2004; 29: 1628-1636
34. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991; 251: 947-950
35. Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore E, et al. The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology (Berl) 2009; 207: 35-45
36. Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, Robbins TW. Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology (Berl) 2004; 176: 331-342
37. la Fougere C, Meisenzahl E, Schmitt G, Stauss J, Frodl T, Tatsch K, et al. D2 receptor occupancy during high- And low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. J Nucl Med 2005; 46: 1028-1033
38. Bitsios P, Roussos P. Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. Pharmacogenomics 2011; 12: 559-566
39. Llerena A, Berecz R, Penas-Lledo E, Suveges A, Farinas H. Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 2013; 14: 177-194
40. Diaz-Asper CM, Weinberger DR, Goldberg TE. Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeutics. NeuroRx 2006; 3: 97-105
41. Berridge CW, Arnsten AF. Psychostimulants and motivated behavior: arousal and cognition. Neurosci Biobehav Rev 2013; 37: 1976-1984
42. Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-Adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 2010; 49: 1011-1023
43. Hakkarainen JJ, Jalkanen AJ, Kaariainen TM, Keski-Rahkonen P, Venalainen T, Hokkanen J, et al. Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int J Pharm 2010; 402: 27-36
44. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186-6191
45. Hamidovic A, Dlugos A, Palmer AA, De Wit H. Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr Genet 2010; 20: 85-92
46. Hart AB, De Wit H, Palmer AA. Candidate gene studies of a promising intermediate phenotype: failure to replicate. Neuropsychopharmacology 2013; 38: 802-816
47. Wardle MC, Hart AB, Palmer AA, De Wit H. Does COMT genotype influence the effects of d-Amphetamine on executive functioning? Genes Brain Behav 2013; 12: 13-20
48. Cheon KA, Jun JY, Cho DY. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. Int Clin Psychopharmacol 2008; 23: 291-298
49. Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50: 1129-39 e2
50. Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, et al. Catechol-Omethyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 1431-1435
51. Park S, Kim JW, Kim BN, Shin MS, Yoo HJ, Cho SC. Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea. J Psychopharmacol 2014; 28: 671-676
52. McGough JJ, McCracken JT, Loo SK, Manganiello M, Leung MC, Tietjens JR, et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2009; 48: 1155-1164.
53. Sengupta S, Grizenko N, Schmitz N, Schwartz G, Bellingham J, Polotskaia A, et al. COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD. Neuropsychopharmacology 2008; 33: 3069-3077
54. Salatino-Oliveira A, Genro JP, Zeni C, Polanczyk GV, Chazan R, Guimaraes AP, et al. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2011; 70: 216-221
55. Contini V, Victor MM, Bertuzzi GP, Salgado CA, Picon FA, Grevet EH, et al. No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD. J Clin Psychopharmacol 2012; 32: 820-823
56. McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill L, Tierney E, et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J 2014; 14: 295-302
57. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007; 32: 1011-1020
58. Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-Omethyltransferase inhibition. Biol Psychiatry 2012; 71: 538-544
59. Giakoumaki SG, Roussos P, Bitsios P. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158-Met polymorphism. Neuropsychopharmacology 2008; 33: 3058-3068
60. Ashare RL, Wileyto EP, Ruparel K, Goelz PM, Hopson RD, Valdez JN, et al. Effects of tolcapone on working memory and brain activity in abstinent smokers: a proof-ofconcept study. Drug Alcohol Depend 2013; 133: 852-856
61. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005; 20: 15-27
62. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612-627
63. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56: 677-682
64. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161: 1798-1805
65. Bosia M, Zanoletti A, Spangaro M, Buonocore M, Bechi M, Cocchi F, et al. Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment. Psychiatry Res 2014; 217: 9-14
66. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007; 90: 86-96
67. Mata I, Arranz MJ, Staddon S, Lopez-Ilundain JM, Tabares-Seisdedos R, Murray RM. The high-Activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. Psychiatr Genet 2006; 16: 213-216
68. Rebollo-Mesa I, Picchioni M, Shaikh M, Bramon E, Murray R, Toulopoulou T. COMT (Val(158/108)Met) genotype moderates the impact of antipsychotic medication on verbal IQ in twins with schizophrenia. Psychiatr Genet 2011; 21: 98-105
69. Arts B, Simons CJ, Drukker M, Van Os J. Antipsychotic medications and cognitive functioning in bipolar disorder: moderating effects of COMT Val108/158 Met genotype. BMC psychiatry 2013; 13: 63
70. Mueller EM, Makeig S, Stemmler G, Hennig J, Wacker J. Dopamine effects on human error processing depend on catechol-O-methyltransferase VAL158MET genotype. J Neurosci 2011; 31: 15818-15825
71. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21: RC121
72. Ghahremani DG, Lee B, Robertson CL, Tabibnia G, Morgan AT, De Shetler N, et al. Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci 2012; 32: 7316-7324
73. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594-596
74. Kayser AS, Allen DC, Navarro-Cebrian A, Mitchell JM, Fields HL. Dopamine, corticostriatal connectivity, and intertemporal choice. J Neurosci 2012; 32: 9402-9409
75. Apud JA, Weinberger DR. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 2007; 21: 535-557
76. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-3719
77. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-636
78. Floresco SB. Prefrontal dopamine and behavioral flexibility: shifting from an "inverted-U" toward a family of functions. Front Neurosci 2013; 7: 62
79. Ryan SG. Regression to the truth: replication of association in pharmacogenetic studies. Pharmacogenomics 2003; 4: 201-207
80. Bakker PR, Van Harten PN, Van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a metaanalysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544-556
81. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930-1933
82. Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol Psychiatry 2009; 66: 997-1004
83. Zhao QZ, Liu BC, Zhang J, Wang L, Li XW, Wang Y, et al. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr Genet 2012; 22: 298-299
84. Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009; 9: 311-318